The global healthcare landscape is currently witnessing a profound structural realignment, as the specialised sector of women’s health technology, femtech, transitions from a niche venture category into a cornerstone of institutional investment and public market interest. As the industry moves through the 2026–2027 window, the convergence of clinical-grade digital platforms, advanced molecular diagnostics, and the aggressive integration of artificial intelligence has created

As the global healthcare sector approaches the 2026 fiscal year, the capital markets are poised for a definitive structural transformation. Following a tumultuous half-decade characterized by the exuberant highs of the Zero Interest Rate Policy (ZIRP) era and the subsequent liquidity crunch of 2022–2024, the IPO landscape has entered a phase of "Rational Exuberance." This new paradigm is defined not by the speculative fervour that drove the 2020–2021 vintage, but by a discipl